Table 2 Information on anticoagulation in the study groups
| Â | VKA (n = 1021) | DOAC (n = 426) | Total (n = 1447) | p |
|---|---|---|---|---|
Type OAC, [n (%)] | ||||
 VKA | 1021 (100.0) | 0 (0.0) | 1021 (70.6) |  |
 DOAC | ||||
  Rivaroxaban | – | 362 (85.0) | 362 (25.0) |  |
  Apixaban | – | 44 (10.3) | 44 (3.0) |  |
  Edoxaban | – | 5 (1.2) | 5 (0.3) |  |
  Dabigatran | – | 15 (3.5) | 15 (1.0) | < 0.001 |
Indication OAC, [n (%)] | ||||
 Atrial fibrillation | 546 (53.5) | 294 (69.0) | 840 (58.1) |  |
 Mechanical heart valve | 34 (3.3) | 3 (0.7) | 37 (2.6) |  |
 Thromboembolic event | 175 (17.1) | 77 (18.1) | 252 (17.4) |  |
 Post-surgery | 0 (0.0) | 6 (1.4) | 6 (0.4) |  |
 Other | 20 (2.0) | 4 (0.9) | 24 (1.7) |  |
 Not documented | 246 (24.1) | 42 (9.9) | 288 (19.9) | < 0.001 |